

Cerulean Pharma Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 08-Feb-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 10

 Phase 2 Clinical..... 11

 Discovery..... 23

[Return to Table of Contents](#)

Cerulean Pharma Inc

COMPANY OVERVIEW

Company Name	Cerulean Pharma Inc
Parent Company Name	Cerulean Pharma Inc
Website	http://ceruleanrx.com/
Country	US
Number of Drugs in Active Development	4
Number of Inactive Drugs	1
Number of Patents as Owner	26
Number of Patents as Third Party	3
Number of Deals	1
Key Indications	Cancer,Breast tumor,Non-small-cell lung cancer,Ovary tumor,Stomach tumor,Renal tumor,Cardiovascular disease,Advanced solid tumor,Rectal tumor,Small-cell lung cancer
Key Target-based Actions	Topoisomerase I inhibitor,Hypoxia inducible factor-1 alpha inhibitor,Proteasome inhibitor,Topoisomerase II inhibitor,DHFR inhibitor,DNA polymerase inhibitor,Hemagglutinin inhibitor,Hemagglutinin modulator,JAK tyrosine kinase inhibitor,PLK1 gene inhibitor,Thymidylate synthase inhibitor,Transferase inhibitor,VEGF receptor antagonist
Key Technologies	Nanoparticle formulation,Small molecule therapeutic,PEGylated formulation,Intravenous formulation,Nanoparticle formulation injectable,Biological therapeutic,Oligonucleotide,Formulation preservation,Peptide,Controlled release formulation

COMPANY PROFILE

SUMMARY

Cerulean Pharma (formerly Tempo Pharmaceuticals Inc) is a biopharmaceutical company specializing in the development of nanoparticle-based therapeutics for oncology, autoimmune and inflammatory diseases, based on its Nanocell technology that was exclusively licensed from the Massachusetts Institute of Technology. In October 2008, the company changed its name to Cerulean Pharma.

FINANCIAL

In January 2015, the company entered into a loan and security agreement with Hercules Technology Growth Capital for a term loan of up to \$26.0 million and completed a private placement for \$1.0 million of Cerulean common stock with Hercules. Cerulean issued Hercules a warrant to purchase 171,901 shares of Cerulean common stock at an exercise price of \$6.05 per share. At that time, Hercules purchased 135,501 shares of unregistered Cerulean common stock at \$7.38 per share for an aggregate purchase price of \$1.0 million.

In April 2014, Cerulean priced its IPO of 8,500,000 shares of its common stock US \$7.00 per share. Underwriters were granted a 30-day option to purchase an additional 1,275,000 shares. Stock to be listed on the NASDAQ Global Market under the ticker symbol 'CERU'. At that time, the offering was expected to close on April 15, 2014. Later that month, the offering was closed. In May 2014, underwriters for the IPO exercised their over-allotment option and purchased an additional 1,069,715 shares, bringing total number of shares sold to 9,569,715 shares and total gross proceeds to \$67 million.

In December 2011, Cerulean raised \$15 million from a series D financing.

In November 2010, Cerulean raised \$24 million from a series C financing.

In July 2009, Cerulean raised \$10 million from a series B-1 financing.

In January 2008, Tempo raised \$8.1 million from a series B financing.

[Return to Table of Contents](#)



In May 2007, Tempo raised \$12.1 million from a series A financing round.


In December 2006, Tempo raised \$2 million from a seed round.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	4	1	5
Endocrine disease	2	0	2
Gynecology and obstetrics	2	0	2
Gastrointestinal disease	1	0	1
Respiratory disease	1	0	1
Genitourinary disease	1	0	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	2
Discovery	2
No Development Reported	1

[Return to Table of Contents](#)

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Development/Commercialization License	0	0	1	0	1

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	2	6
Genitourinary disease	1	2
Gastrointestinal disease	1	1
Gynecology and obstetrics	0	1
Respiratory disease	0	1
Endocrine disease	0	1

Trials by Phase

Phase	Ongoing	All
Phase 2	1	3
Phase 1	1	3

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	10	1	11
Endocrine disease	12	0	12
Gastrointestinal disease	12	0	12
Genitourinary disease	8	0	8
Growth disorder	1	0	1

[Return to Table of Contents](#)



Hematological disease	4	0	4
Degeneration	2	0	2
Andrology	2	0	2
Immune disorder	15	1	16
Psychiatric disorder	1	0	1
Musculoskeletal disease	6	0	6
Neoplasm	24	1	25
Ocular disease	2	0	2
Genetic disorder	2	0	2
Metabolic disorder	11	0	11
Neurological disease	6	0	6
Nutritional disorder	3	0	3
Respiratory disease	6	2	8
Infectious disease	5	2	7
Inflammatory disease	14	1	15
Otorhinolaryngological disease	1	0	1
Gynecology and obstetrics	8	0	8
Dermatological disease	6	0	6

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

camptothecin nanoparticle (cancer), Cerulean Pharma

camptothecin nanoparticle (cancer), Cerulean Pharma SNAPSHOT

Drug Name	camptothecin nanoparticle (cancer), Cerulean Pharma
Key Synonyms	
Originator Company	Calando Pharmaceuticals Inc
Active Companies	Cerulean Pharma Inc
Inactive Companies	Calando Pharmaceuticals Inc
Highest Status	Phase 2 Clinical
Active Indications	Small-cell lung cancer;Non-small-cell lung cancer;Renal tumor;Ovary tumor;Stomach tumor;Rectal tumor
Target-based Actions	Topoisomerase I inhibitor;Hypoxia inducible factor-1 alpha inhibitor
Other Actions	Synergist;Anticancer
Technologies	Nanoparticle formulation injectable;Controlled release formulation;Small molecule therapeutic;Intravenous formulation
Last Change Date	20-Jan-2015

camptothecin nanoparticle (cancer), Cerulean Pharma DEVELOPMENT PROFILE

SUMMARY

Cerulean Pharma, under license from Calando, following its merger with Insert in April 2008, is developing a nanoparticle-drug conjugate, CRLX-101 (formerly IT-101), an iv Cycloset formulation of camptothecin (structure shown), a topoisomerase and hypoxia inducible factor-1 alpha inhibitor, for the potential treatment of cancer, including gastric, ovarian, renal, rectal, prostate and non-small cell lung cancer (NSCLC),,,. In June 2011, a phase II trial in NSCLC was initiated. In June 2012, a phase Ib/IIa trial in relapsed renal cell carcinoma was initiated. In October 2014, a phase II trial for advanced renal cell carcinoma was initiated in the US and at that time, the trial was expected to be completed in February 2016. In July 2012, the first patient was dosed in a phase II trial for ovarian cancer. In January 2013, the first patient was dosed in a phase II trial for gastric cancer. In January 2013, a phase II trial in extensive-stage small-cell-lung cancer (SCLC) was initiated. In October 2013, a phase Ib/II study was ongoing to assess the activity of neo-adjuvant CRLX-101 in combination with capecitabine and radiotherapy for rectal cancer. In January 2015, initiate data from the trial were presented. In February 2014, a phase II ovarian cancer study of CRLX-101 in combination with Avastin was initiated in the US ; in August 2014, proof-of-principle data were expected in the in the first quarter of 2015. In October 2011, the company was seeking to outlicense the drug.

Calando was previously developing CRLX-10; in September 2008, Calando began a phase II ovarian cancer trial ; however, in June 2009, the trial was terminated due to poor recruitment.

camptothecin nanoparticle (cancer), Cerulean Pharma DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS

[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Cerulean Pharma Inc	Non-small-cell lung cancer	Russian Federation	Phase 2 Clinical	29-Jun-2011
Cerulean Pharma Inc	Non-small-cell lung cancer	Ukraine	Phase 2 Clinical	29-Jun-2011
Cerulean Pharma Inc	Ovary tumor	US	Phase 2 Clinical	23-Jun-2009
Cerulean Pharma Inc	Rectal tumor	US	Phase 2 Clinical	21-Oct-2013
Cerulean Pharma Inc	Renal tumor	US	Phase 2 Clinical	21-Jun-2012
Cerulean Pharma Inc	Small-cell lung cancer	US	Phase 2 Clinical	31-Jan-2013
Cerulean Pharma Inc	Stomach tumor	US	Phase 2 Clinical	30-Nov-2012
Calando Pharmaceuticals Inc	Ovary tumor	US	Discontinued	03-Jun-2009

camptothecin nanoparticle (cancer), Cerulean Pharma CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
7689-03-4	1
	
Name	Type
Camposomes	Trade Name
camptothecin	

[Return to Table of Contents](#)

camptothecin nanoparticle (cancer), Cerulean Pharma DRUG NAMES

Names	Type
Cycloset-camptothecin, Calando	
CRLX-101	Research Code
Cycloset-camptothecin, Cerulean Pharma	
IT-101	Research Code
camptothecin nanoparticle (cancer), Cerulean Pharma	
Cycloset-camptothecin, Insert Therapeutics	
CRLX-101-202	Research Code
camptothecin	

camptothecin nanoparticle (cancer), Cerulean Pharma CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Ovary tumor											
0	0	0	0	0	2	0	0	0	0	0	2
Renal cell carcinoma											
0	0	0	0	1	1	0	0	0	0	1	1
Metastatic esophageal cancer											
0	0	0	0	1	1	0	0	0	0	1	1
Rectal tumor											
0	0	0	0	0	0	1	1	0	0	1	1
Metastatic stomach cancer											
0	0	0	0	1	1	0	0	0	0	1	1
Metastatic non small cell lung cancer											
0	0	0	0	0	1	0	0	0	0	0	1
Small-cell lung cancer											
0	0	0	0	0	1	0	0	0	0	0	1

[Return to Table of Contents](#)

Fallopian tube cancer											
0	0	0	0	0	1	0	0	0	0	0	1
Metastatic renal cancer											
0	0	0	0	0	0	0	1	0	0	0	1
Peritoneal tumor											
0	0	0	0	0	1	0	0	0	0	0	1
Advanced solid tumor											
0	0	0	0	0	0	0	1	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	2	6	1	3	0	0	3	9

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Arrowhead Research Corp	1	0	1	0	2
Cerulean Pharma Inc	0	0	1	0	1
City of Hope	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1
Drug - Development Services	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Arrowhead Research Corp	6	3	9
Cerulean Pharma Inc	8	0	8
California Institute of Technology	3	0	3
Individual	3	0	3
Blend Therapeutics Inc	0	1	1
Avidity NanoMedicines LLC	1	0	1
City of Hope	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Formulation	6
New use	3
General interest	2
Product	1
Component of Combination	1
Delivery device	1

[Return to Table of Contents](#)

docetaxel (Cyclodextrin Nanoparticle Technology), Cerulean

docetaxel (Cyclodextrin Nanoparticle Technology), Cerulean SNAPSHOT

Drug Name	docetaxel (Cyclodextrin Nanoparticle Technology), Cerulean
Key Synonyms	
Originator Company	Cerulean Pharma Inc
Active Companies	Cerulean Pharma Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Advanced solid tumor;Cancer
Target-based Actions	
Other Actions	Microtubule inhibitor;Anticancer;Cell cycle inhibitor
Technologies	Nanoparticle formulation injectable;Small molecule therapeutic;Intravenous formulation
Last Change Date	30-Jan-2015

docetaxel (Cyclodextrin Nanoparticle Technology), Cerulean DEVELOPMENT PROFILE

SUMMARY

Cerulean is developing CRLX-301, a cyclodextrin nanoparticle formulation of docetaxel, developed using its dynamic tumor targeting platform, for the potential iv treatment of cancer including advanced solid tumors. In December 2014, a phase I/IIa trial was initiated in Australia, in patients with solid tumors.

The company is also investigating CRLX-288, a PEGylated polymeric nanoparticle technology docetaxel.

docetaxel (Cyclodextrin Nanoparticle Technology), Cerulean DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Cerulean Pharma Inc	Advanced solid tumor	Australia	Phase 2 Clinical	17-Dec-2014
Cerulean Pharma Inc	Cancer	US	Discovery	10-Mar-2012

docetaxel (Cyclodextrin Nanoparticle Technology), Cerulean CHEMICAL STRUCTURES

[Return to Table of Contents](#)



CAS Registry Number:	Confidence Level:
114977-28-5	1
	
Name	Type
docetaxel	INN; USAN
Tyxan	Trade Name
Taxotere	Trade Name
Monotaxel	Trade Name
PEG-TX1	Trade Name
MBP-Y004	Research Code
SP-1012C	Research Code
NKTR-105	Research Code
CRLX-288	Research Code
SD-009	Research Code
ML-061	Research Code
BIND-014	Research Code
SYP-0704A	Research Code
NMR-1827	Research Code
RP-56976	Research Code
ATI-1123	Research Code
docetaxel-PNP	
docetaxel-PM	

[Return to Table of Contents](#)

docetaxel (Cyclodextrin Nanoparticle Technology), Cerulean DRUG NAMES

Names	Type
CRLX-301	Research Code
docetaxel (Cyclodextrin Nanoparticle Technology), Cerulean	

docetaxel (Cyclodextrin Nanoparticle Technology), Cerulean CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Advanced solid tumor											
0	0	0	0	0	0	0	1	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	1	0	0	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Cerulean Pharma Inc	3	0	3

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Formulation	2
General interest	1

siRNA-containing polymeric nanoparticle technology (cancer), Cerulean

siRNA-containing polymeric nanoparticle technology (cancer), Cerulean SNAPSHOT

Drug Name	siRNA-containing polymeric nanoparticle technology (cancer), Cerulean
Key Synonyms	
Originator Company	Cerulean Pharma Inc
Active Companies	Cerulean Pharma Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Breast tumor
Target-based Actions	
Other Actions	Anticancer;siRNA agent
Technologies	Nanoparticle formulation;Biological therapeutic;Oligonucleotide
Last Change Date	24-Sep-2014

siRNA-containing polymeric nanoparticle technology (cancer), Cerulean DEVELOPMENT PROFILE

SUMMARY

Cerulean is investigating a siRNA-containing polymeric nanoparticle technology formulation for the potential treatment of cancer. By March 2012, preclinical studies were ongoing ; in September 2014, development was ongoing.

siRNA-containing polymeric nanoparticle technology (cancer), Cerulean DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Cerulean Pharma Inc	Breast tumor	US	Discovery	10-Mar-2012

siRNA-containing polymeric nanoparticle technology (cancer), Cerulean DRUG NAMES

Names	Type
siRNA-containing polymeric nanoparticle technology (cancer), Cerulean	

[Return to Table of Contents](#)

CRLX-522

CRLX-522 SNAPSHOT

Drug Name	CRLX-522
Key Synonyms	
Originator Company	Cerulean Pharma Inc
Active Companies	Cerulean Pharma Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	
Other Actions	Anticancer
Technologies	Nanoparticle formulation;Small molecule therapeutic
Last Change Date	17-Apr-2014

CRLX-522 DEVELOPMENT PROFILE

SUMMARY

Cerulean is investigating CRLX-522, a cabazitaxel nanoparticle formulation, for the potential treatment of cancer. In April 2014, preclinical data were presented.

CRLX-522 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Cerulean Pharma Inc	Cancer	US	Discovery	08-Apr-2014

CRLX-522 DRUG NAMES

Names	Type
CRLX-522	Research Code
cabazitaxel nanoparticle (cancer), Cerulean	

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

